1. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease. New England Journal of Medicine. 2012;367:795–804.
2. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. The Lancet Neurology. 2013;12:357–67.
3. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA. 2015;313:1924.
4. Baker JE, Lim YY, Pietrzak RH, Hassenstab J, Snyder PJ, Masters CL, et al. Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2017;6:108–21.
5. Elias MF, Beiser A, Wolf PA, Au R, White RF, D’Agostino RB. The Preclinical Phase of Alzheimer Disease. Archives of Neurology. 2000;57:808.
6. Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer’s disease. Journal of the International Neuropsychological Society : JINS. 2008;14:266–78.
7. Derby CA, Burns LC, Wang C, Katz MJ, Zimmerman ME, L’Italien G, et al. Screening for predementia AD: Time-dependent operating characteristics of episodic memory tests. Neurology. 2013;80:1307–14.
8. Burnham SC, Bourgeat P, Doré V, Savage G, Brown B, Laws S, et al. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer’s disease pathophysiology (SNAP) or Alzheimer’s disease pathology: a longitudinal study. The Lancet Neurology. 2016;15:1044–53.
9. Xiong C, Luo J, Morris JC, Bateman R. Linear combinations of multiple outcome measures to improve the power of efficacy analysis – application to clinical trials on early-stage Alzheimer’s disease. Biostatistics & Epidemiology. 2017;1:36–58.
10. Glodzik-Sobanska L, Reisberg B, De Santi S, Babb JS, Pirraglia E, Rich KE, et al. Subjective Memory Complaints: Presence, Severity and Future Outcome in Normal Older Subjects. Dementia and Geriatric Cognitive Disorders. 2007;24:177–84.
11. Dufouil C, Fuhrer R, Alpérovitch A. Subjective Cognitive Complaints and Cognitive Decline: Consequence or Predictor? The Epidemiology of Vascular Aging Study. Journal of the American Geriatrics Society. 2005;53:616–21.
12. Oijen M van, Jong FJ de, Hofman A, Koudstaal PJ, Breteler MMB. Subjective memory complaints, education, and risk of Alzheimer’s disease. Alzheimer’s & dementia. 2007;3:92–7.
13. Reisberg B, Shulman MB, Torossian C, Leng L, Zhu W. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimer’s & Dementia. 2010;6:11–24.
14. Slot RE, Sikkes SA, Berkhof J, Brodaty H, Buckley R, Cavedo E, et al. Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia. Alzheimer’s & Dementia. 2019;15:465–76.
15. Wang Y, Risacher SL, West JD, McDonald BC, MaGee TR, Farlow MR, et al. Altered Default Mode Network Connectivity in Older Adults with Cognitive Complaints and Amnestic Mild Cognitive Impairment. Journal of Alzheimer’s Disease. 2013;35:751–60.
16. Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ. Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Archives of neurology. 2012;69:223–9.
17. Amariglio RE, Becker JA, Carmasin J, Wadsworth LP, Lorius N, Sullivan C, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012;50:2880–6.
18. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund L-O, Freund-Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. The Lancet Neurology. 2009;8:619–27.
19. Jessen F, Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller F, Kölsch H, et al. Prediction of Dementia by Subjective Memory Impairment. Archives of General Psychiatry. 2010;67:414–22.
20. Jessen F, Amariglio RE, Boxtel M van, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s & Dementia. 2014;10:844–52.
21. Rabin LA, Smart CM, Amariglio RE. Subjective Cognitive Decline in Preclinical Alzheimer’s Disease. Annual review of clinical psychology. 2017;13:369–96.
22. Starkstein SE. Anosognosia in Alzheimer’s disease: Diagnosis, frequency, mechanism and clinical correlates. Cortex. 2014;61:64–73.
23. Clare L, Marková IS, Roth I, Morris RG. Awareness in Alzheimer’s disease and associated dementias: Theoretical framework and clinical implications. Aging & Mental Health. 2011;15:936–44.
24. Tondelli M, Barbarulo AM, Vinceti G, Vincenzi C, Chiari A, Nichelli PF, et al. Neural Correlates of Anosognosia in Alzheimer’s Disease and Mild Cognitive Impairment: A Multi-Method Assessment. Frontiers in Behavioral Neuroscience. 2018;12:1–11.
25. Cacciamani F, Tandetnik C, Gagliardi G, Bertin H, Habert M-O, Hampel H, et al. Low Cognitive Awareness, but Not Complaint, is a Good Marker of Preclinical Alzheimer’s Disease. Journal of Alzheimer’s disease : JAD. 2017;59:753–62.
26. Vannini P, Hanseeuw BJ, Munro CE, Amariglio RE, Marshall GA, Rentz DM, et al. Hippocam- pal hypometabolism in older adults with memory complaints and increased amyloid burden. Neurology. 2017;88:1759–67.
27. Perrotin A, Desgranges B, Landeau B, Mézenge F, La Joie R, Egret S, et al. Anosognosia in Alzheimer disease: Disconnection between memory and self-related brain networks. Annals of Neurology. 2015;78:477–86.
28. Vannini P, Hanseeuw B, Munro CE, Amariglio RE, Marshall GA, Rentz DM, et al. Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging. NeuroImage: Clinical. Elsevier; 2017;15:408–14.
29. Edmonds EC, Weigand AJ, Thomas KR, Eppig J, Delano-Wood L, Galasko DR, et al. Increasing Inaccuracy of Self-Reported Subjective Cognitive Complaints Over 24 Months in Empirically Derived Subtypes of Mild Cognitive Impairment. Journal of the International Neuropsychological Society. 2018;24:842–53.
30. Munro CE, Donovan NJ, Amariglio RE, Papp KV, Marshall GA, Rentz DM, et al. The Impact of Awareness of and Concern About Memory Performance on the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease Dementia. The American Journal of Geriatric Psychiatry. 2018;26:896–904.
31. Therriault J, Ng KP, Pascoal TA, Mathotaarachchi S, Kang MS, Struyfs H, et al. Anosognosia predicts default mode network hypometabolism and clinical progression to dementia. Neurology. 2018;90:e932–9.
32. Vannini P, Amariglio R, Hanseeuw B, Johnson KA, McLaren DG, Chhatwal J, et al. Memory self- awareness in the preclinical and prodromal stages of Alzheimer’s disease. Neuropsychologia. 2017;99:343–9.
33. Epelbaum S, Genthon R, Cavedo E, Habert MO, Lamari F, Gagliardi G, et al. Preclinical Alzheimer’s disease: A systematic review of the cohorts underlying the concept. Alzheimer’s & Dementia. 2017;13:454–67.
34. Dubois B, Epelbaum S, Nyasse F, Bakardjian H, Gagliardi G, Uspenskaya O, et al. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer’s disease (INSIGHT-preAD): a longitudinal observational study. The Lancet Neurology. 2018;17:335–46.
35. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. Journal of Psychiatric Research. 1975;12:189–98.
36. Rattanabannakit C, Risacher SL, Gao S, Lane KA, Brown SA, McDonald BC, et al. The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests. Abbate C, editor. Journal of Alzheimer’s Disease. 2016;51:1145–55.
37. Grober E, Buschke H. Genuine memory deficits in dementia. Developmental neuropsychology. 1987;3:13–36.
38. Barbeau EJ, Didic M, Tramoni E, Felician O, Joubert S, Sontheimer A, et al. Evaluation of visual recognition memory in MCI patients. Neurology. 2004;62:1317–22.
39. Rey A. L’examen psychologique dans les cas d’encephalopathie traumatique. Archives Psychologiques. 1941;28:286–340.
40. Rey A. L’examen clinique en psychologie. Paris: Presses Universitaires De France; 1958.
41. Wechsler D. Manual for the Wechsler Memory Scale—Revised. San Antonio: TX: The Psychological Corporation; 1987.
42. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. The American journal of psychiatry. 1984;141:1356–64.
43. Monahan P, Alder C, Khan B, Stump T, Boustani M. The Healthy Aging Brain Care (HABC) Monitor: validation of the Patient Self-Report Version of the clinical tool designed to measure and monitor cognitive, functional, and psychological health. Clinical Interventions in Aging. 2014;9:2123.
44. Farias ST, Mungas D, Reed BR, Cahn-Weiner D, Jagust W, Baynes K, et al. The measurement of everyday cognition (ECog): Scale development and psychometric properties. Neuropsychology. 2008;22:531– 44.
45. Dalla Barba G, Parlato V, Iavarone A, Boller F. Anosognosia, intrusions and ‘frontal’ functions in Alzheimer’s disease and depression. Neuropsychologia. 1995;33:247–59.
46. Habert M-O, Bertin H, Labit M, Diallo M, Marie S, Martineau K, et al. Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds. Annals of Nuclear Medicine. 2018;32:75–86.
47. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiology of Aging. 2011;32:1207–18.
48. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer’s & Dementia. 2015;11:1–15.e1–4.
49. Jack CR, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study. The Lancet Neurology. 2014;13:997–1005.
50. Reisberg B, Gauthier S. Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer’s disease. International Psychogeriatrics. 2008;20:1–16.
51. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. The Lancet Neurology. 2010;9:119–28.
52. Stuss DT, Picton TW, Alexander MP. Consciousness, Self-Awareness, and the Frontal Lobes. In: Salloway SP, Malloy PF, Duffy JD, editors. The frontal lobes and neuropsychiatric illness. Arlington, VA, US: American Psychiatric Publishing, Inc.. 2001. pp. 101–9.
53. Antoine C, Antoine P, Guermonprez P, Frigard B. Conscience des déficits et anosognosie dans la maladie d’Alzheimer. L’Encéphale. 2004;30:570–7.
54. Giannakopoulos P, Gold G, Gunten A von, Hof PR, Bouras C. Pathological substrates of cognitive decline in Alzheimer’s disease. Frontiers of neurology and neuroscience. 2009;24:20–9.
55. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years. Journal of Neuropathology & Experimental Neurology. 2011;70:960–9.
56. Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, Flier WM van der, Berckel BNM van, et al. Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA. 2015;313:1939.
57. Grothe MJ, Barthel H, Sepulcre J, Dyrba M, Sabri O, Teipel SJ, et al. In vivo staging of regional amyloid deposition. Neurology. 2017;89:2031–8.
58. Hanseeuw BJ, Scott MR, Sikkes SAM, Properzi M, Gatchel JR, Salmon E, et al. Evolution of anosognosia in alzheimer’s disease and its relationship to amyloid. Annals of Neurology. 2020;87:267–80.
59. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer’s & Dementia. 2013;9:63–75.e2.
60. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimer’s & Dementia. 2015;11:718–26.
61. Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, et al. Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry. 2018;75:84.